BofA IG Healthcare Weekly: Vital Signs

Research evidence excerpt

BofA IG Healthcare Weekly: Vital Signs

Accessible version

BofA IG Healthcare Weekly

Vital Signs

Industry Overview

Healthcare Highlights: VRTX, NOVNSW, AZN 10 July 2026

Vertex Pharmaceuticals announced the acquisition of Crinetics Pharmaceuticals for $10 High Grade Credit

billion, with an expected close in the third quarter of this year. The deal adds potential United States

best-in-class commercialized and Phase 3 endocrinology assets with $5 billion in peak Healthcare

sales opportunity. Novartis announced the acquisition of Myricx Bio for $1.1 billion upfront Andrew Kaplan

and up to $400 million in potential milestones. The deal is expected to close in the second Research Analyst

half of the year and strengthens the oncology pipeline with two lead ADC assets, as well as BofAS+1 646 855 8748

a broader payload platform with potential impact across multiple solid tumor settings. andrew.kaplan@bofa.com

AstraZeneca announced that the CARDIO-TTRansform Phase 3 trial for Wainua Vritika Patni

Research Analyst

(eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy did not meet BofAS

the primary endpoint. +1 646 855 7042

vritika.patni@bofa.com

Healthcare underperformed the IG Index last week

The ICE BofA IG Healthcare index underperformed the ICE BofA IG index, at -0.59%

versus -0.47% on a total-return basis. Medical Products led other subsectors, with a total

return of -0.42%. In Europe, Healthcare underperformed the ICE BofA EMU index, at Stock symbols and abbreviations

-0.67% versus -0.53%. VRTX Vertex Pharmaceuticals

NOVNSW Novartis

YTD, healthcare outperformed on total return AZNOAS AstraZenecaOption adjusted spread

YTD, IG Healthcare outperformed the ICE BofA IG index, at a total return of 0.52% versus YTD Year to date